Hi Semi
Interesting point you raise.
Just been into the Acuity website
"All Sectors use ATMs
ATMs are a capital management tool used extensively in the United States since the 1990s by listed companies to unlock capital, mitigate risk, pay down debt, fine tune the balance sheet and optimise their cost of capital.
1,182 US companies utilised ATMs to raise $173 billion between 2008 and 2016 (with many more establishing an ATM without actually utilising it. E.g. in 2016 $30 billion was raised using ATMs, though over $100+ billion was available under ATM programs).
ATMs are used across all sectors by companies of all sizes, from the largest industrials to the smallest of growth companies".
With the AI tech application coming up for the FDA approval in March and then the subsequent ticking off for for this approval - all sorts of doors will open up and quickly.
Slicing some open with painful surgery to check out the liver as opposed to using the painless more effective MRI, AI technology with Ferriscan and Ferrismart will change the face of liver analysis in medical industry.
It may just be that Resonance Health management want to be in a position to take up any opportunities that need to be funded in the ensuing months. Personally I think the next move in the share price will be substantial. There are so many elements lining up for a substantial boost to revenue which will be repeat/repeat/repeat.
The other possibility is Liver Fibrosis MRI technology. Much work was done on this program and no doubt a mountain of data has been accumulated. It may just be they are now creating a plan to actively engage this program again.
Much to unfold as no doubt there are suitors on the door in possible negotiations for come what may.
It is interesting that so many parties want to get on the distribution list - they have been in the game for years and know what is in the process of unfolding and want to be part of the action.
